BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 21506111)

  • 1. Cytotoxic and immune-sensitizing properties of nitric oxide-modified Saquinavir in iNOS-positive human melanoma cells.
    Mijatovic S; Maksimovic-Ivanic D; Mojic M; Timotijevic G; Miljkovic D; Mangano K; Donia M; Di Cataldo A; Al-Abed Y; Cheng KF; Stosic-Grujicic S; Nicoletti F
    J Cell Physiol; 2011 Jul; 226(7):1803-12. PubMed ID: 21506111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unique antineoplastic profile of Saquinavir-NO, a novel NO-derivative of the protease inhibitor Saquinavir, on the in vitro and in vivo tumor formation of A375 human melanoma cells.
    Donia M; Mangano K; Fagone P; De Pasquale R; Dinotta F; Coco M; Padron J; Al-Abed Y; Giovanni Lombardo GA; Maksimovic-Ivanic D; Mijatovic S; Zocca MB; Perciavalle V; Stosic-Grujicic S; Nicoletti F
    Oncol Rep; 2012 Aug; 28(2):682-8. PubMed ID: 22665020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Saquinavir-NO-targeted S6 protein mediates sensitivity of androgen-dependent prostate cancer cells to TRAIL.
    Mojic M; Mijatovic S; Maksimovic-Ivanic D; Dinic S; Grdovic N; Miljkovic D; Stosic-Grujicic S; Tumino S; Fagone P; Mangano K; Zocca MB; Al-Abed Y; McCubrey JA; Nicoletti F
    Cell Cycle; 2012 Mar; 11(6):1174-82. PubMed ID: 22370480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
    Hamaï A; Richon C; Meslin F; Faure F; Kauffmann A; Lecluse Y; Jalil A; Larue L; Avril MF; Chouaib S; Mehrpour M
    Oncogene; 2006 Dec; 25(58):7618-34. PubMed ID: 16983347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The antitumor properties of a nontoxic, nitric oxide-modified version of saquinavir are independent of Akt.
    Maksimovic-Ivanic D; Mijatovic S; Miljkovic D; Harhaji-Trajkovic L; Timotijevic G; Mojic M; Dabideen D; Cheng KF; McCubrey JA; Mangano K; Al-Abed Y; Libra M; Garotta G; Stosic-Grujicic S; Nicoletti F
    Mol Cancer Ther; 2009 May; 8(5):1169-78. PubMed ID: 19417156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic potential of nitric oxide-modified drugs in colon cancer cells.
    Mojic M; Mijatovic S; Maksimovic-Ivanic D; Miljkovic D; Stosic-Grujicic S; Stankovic M; Mangano K; Travali S; Donia M; Fagone P; Zocca MB; Al-Abed Y; McCubrey JA; Nicoletti F
    Mol Pharmacol; 2012 Oct; 82(4):700-10. PubMed ID: 22798453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo anticancer action of Saquinavir-NO, a novel nitric oxide-derivative of the protease inhibitor saquinavir, on hormone resistant prostate cancer cells.
    Donia M; Maksimovic-Ivanic D; Mijatovic S; Mojic M; Miljkovic D; Timotijevic G; Fagone P; Caponnetto S; Al-Abed Y; McCubrey J; Stosic-Grujicic S; Nicoletti F
    Cell Cycle; 2011 Feb; 10(3):492-9. PubMed ID: 21270522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor activity of a novel recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand.
    Fang F; Wang AP; Yang SF
    Acta Pharmacol Sin; 2005 Nov; 26(11):1373-81. PubMed ID: 16225761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cathepsin E enhances anticancer activity of doxorubicin on human prostate cancer cells showing resistance to TRAIL-mediated apoptosis.
    Yasukochi A; Kawakubo T; Nakamura S; Yamamoto K
    Biol Chem; 2010 Aug; 391(8):947-58. PubMed ID: 20482316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels.
    Lu M; Strohecker A; Chen F; Kwan T; Bosman J; Jordan VC; Cryns VL
    Clin Cancer Res; 2008 May; 14(10):3168-76. PubMed ID: 18483385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of Akt signaling by the lignan matairesinol sensitizes prostate cancer cells to TRAIL-induced apoptosis.
    Peuhu E; Rivero-Müller A; Stykki H; Torvaldson E; Holmbom T; Eklund P; Unkila M; Sjöholm R; Eriksson JE
    Oncogene; 2010 Feb; 29(6):898-908. PubMed ID: 19935713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CCAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction and ubiquitin/proteasome-mediated cellular FLICE-inhibitory protein down-regulation contribute to enhancement of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by dimethyl-celecoxib in human non small-cell lung cancer cells.
    Chen S; Liu X; Yue P; Schönthal AH; Khuri FR; Sun SY
    Mol Pharmacol; 2007 Nov; 72(5):1269-79. PubMed ID: 17684158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TRAIL apoptosis is enhanced by quercetin through Akt dephosphorylation.
    Kim YH; Lee YJ
    J Cell Biochem; 2007 Mar; 100(4):998-1009. PubMed ID: 17031854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cationic liposome-mediated nitric oxide synthase gene therapy enhances the antitumor effects of cisplatin in lung cancer.
    Ye S; Yang W; Wang Y; Ou W; Ma Q; Yu C; Ren J; Zhong G; Shi H; Yuan Z; Su X; Zhu W
    Int J Mol Med; 2013 Jan; 31(1):33-42. PubMed ID: 23128378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
    Liu X; Yue P; Chen S; Hu L; Lonial S; Khuri FR; Sun SY
    Cancer Res; 2007 May; 67(10):4981-8. PubMed ID: 17510429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin.
    Zhang XD; Wu JJ; Gillespie S; Borrow J; Hersey P
    Clin Cancer Res; 2006 Feb; 12(4):1355-64. PubMed ID: 16489094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiapoptotic role of endogenous nitric oxide in human melanoma cells.
    Salvucci O; Carsana M; Bersani I; Tragni G; Anichini A
    Cancer Res; 2001 Jan; 61(1):318-26. PubMed ID: 11196180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CHM-1 induces apoptosis via p38-mediated upregulation of DR5 expression in human ovarian cancer SKOV3 cells.
    Lee JC; Chou LC; Huang CH; Chung JG; Huang LJ; Lee KH; Hung MC; Way TD; Kuo SC
    Eur J Pharmacol; 2011 Nov; 670(1):96-104. PubMed ID: 21907193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
    Itashiki Y; Harada K; Ferdous T; Yoshida H
    Anticancer Res; 2007; 27(4B):2365-75. PubMed ID: 17695527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Withaferin A inhibits iNOS expression and nitric oxide production by Akt inactivation and down-regulating LPS-induced activity of NF-kappaB in RAW 264.7 cells.
    Oh JH; Lee TJ; Park JW; Kwon TK
    Eur J Pharmacol; 2008 Dec; 599(1-3):11-7. PubMed ID: 18838070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.